Guggenheim raises target for Elevance Health stock from USD 455 to USD 460

Published on 10/19/2026 at 09:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock costs EUR 382.70 on October 19, 2026. Second-quarter revenue was USD 49.80 billion and adjusted EPS was USD 7.45.

Earnings and valuation markers

Guggenheim lifted its target to USD 460 on October 12, 2026.
Second-quarter revenue reached USD 49.80 billion and adjusted earnings per share were USD 7.45.
Elevance Health stock traded at EUR 382.70 at 9:34 a.m. CEST at Lang & Schwarz on October 19, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at EUR 382.70 at Lang & Schwarz on October 19, 2026 at 9:34 a.m. CEST. The latest analyst move came from Guggenheim, which raised its target from USD 455 to USD 460 on October 12 while maintaining a Buy rating, according to Investing.com.

Three events set the backdrop

On July 15, 2026, Elevance Health reported second-quarter revenue of USD 49.80 billion and adjusted earnings per share of USD 7.45, according to Fortune. On October 5, 2026, the company announced that third-quarter results would be released on October 21, 2026, at 6:00 a.m. Eastern Daylight Time, according to Elevance Health. On October 12, 2026, Guggenheim raised its target from USD 455 to USD 460, according to Investing.com.

What will the October 21 report test?

The upcoming report will test whether the second-quarter earnings base can support the full-year outlook. Elevance Health raised its 2026 adjusted earnings-per-share guidance to at least USD 27.00 after the second quarter, while management also outlined a goal of at least 12 percent adjusted earnings-per-share growth in 2027, according to Business Wire. The comparison matters because second-quarter revenue increased only 0.80 percent year over year, leaving medical membership and cost control as key operating questions.

Next date is October 21

Elevance Health is scheduled to release third-quarter 2026 results on October 21, 2026, before the US market opens, with its management call at 8:30 a.m. Eastern Daylight Time. The company says its businesses serve 104 million consumers, giving the report a broad operating base.

Stock price and valuation context

Elevance Health had a market capitalization of USD 92.9 billion as of October 16, 2026. Its primary exchange is the NYSE, where the finance quote showed a price of USD 428.26 at 4:00 p.m. Eastern Daylight Time on October 16, 2026, against a 52-week range of USD 274.84 to USD 436.24. The euro quotation was trading at EUR 382.70 at Lang & Schwarz on October 19, 2026 at 9:34 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.